Lyka Labs Limited (NSEI: LYKALABS)
Health Care · Pharmaceuticals · IN
Rs73.62
+10.37% today · -26.7% 1Y
Lyka Labs Limited (NSEI: LYKALABS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $27.46M and employs 648 people.
Over the last twelve months the share price has lost 26.7%, trading between 44.10 and 102.99.
Tweenvest scores Lyka Labs Limited across four factors: quality 54/100, value 77/100, growth 53/100. Its strongest factor is value.
LYKALABS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $27.46M
- Revenue (TTM)
- $14.18M
- P/E
- —
- EPS
- -2.51
- Dividend yield
- —
- Beta (5Y)
- 0.56
- 52-week high
- Rs102.99
- 52-week low
- Rs44.10
- Avg volume (3M)
- —
- Shares outstanding
- 35.69M
- Employees
- 648
- Next earnings
- —
About Lyka Labs Limited
Established in 1976 and headquartered in Mumbai, India, Lyka Labs Limited is a pharmaceutical firm specializing in the development, manufacturing, and marketing of a wide array of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses numerous therapeutic areas, including intensive care, gastroenterology, anti-infectives, anti-fungals, surgery, urology, wound care, anesthesia, and various dermatological and cosmeceutical applications like topical steroids, anti-acne, anti-aging, and hair care. These products are available in diverse forms, such as injections, creams, ointments, gels, and lotions. Beyond its own offerings, Lyka Labs also provides contract manufacturing services to other major pharmaceutical companies and offers comprehensive medical and technical support. This support includes manufacturing expertise, facility assistance, and crucial technical data such as molecule stability testing, impurity profiling, and bioequivalence (BA/BE) clinical study data. The company's market reach extends globally, with exports to various countries including Bangladesh, Cambodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam.
- ISIN
- INE933A01014
- Founded
- 1976
- Listed since
- Jan 1, 1996
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.00 | +0.13% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.38 | +0.54% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.13 | +0.21% |
Figures last refreshed Aug 18, 2026.